Physician profile
Marshall Kirsch
NPI 1699301549
$1,847.82
in general payments reported to CMS, 2019-2025
21 companies · $864 in 2025
The $864 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $102 · 2023: $205 · 2024: $677 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $327.09 | 2024-2025 | Briviact, Fintepla |
| Pfizer INC. | $234.61 | 2025 | |
| Jazz Pharmaceuticals INC. | $222.98 | 2023-2025 | Epidiolex |
| Emd Serono, INC. | $221.66 | 2023-2025 | Mavenclad |
| Sk Life Science, INC. | $182.70 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $160.48 | 2024 | |
| Neurelis, INC. | $121.67 | 2024-2025 | Valtoco |
| Abbvie INC. | $64.86 | 2023-2025 | |
| Genentech USA, INC. | $54.55 | 2022-2023 | Enspryng, Ocrevus |
| Genzyme Corporation | $38.23 | 2022 | |
| Biocodex, INC. | $25.75 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $23.72 | 2025 | Rexulti |
| Argenx US, INC. | $23.56 | 2025 | Vyvgart |
| Otter Pharmaceuticals, LLC | $21.07 | 2025 | Sympazan |
| Neurocrine Biosciences, INC. | $19.88 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $19.32 | 2022 | |
| Eisai INC. | $18.93 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $18.85 | 2024 | Andexxa |
| Tg Therapeutics, INC. | $16.98 | 2025 | |
| Horizon Therapeutics Plc | $15.90 | 2022 | |
| Amneal Pharmaceuticals LLC | $15.03 | 2025 | Crexont |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Kirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.